Ireland
--:--IST
Priya Life Science Sponsor trial record
Sponsor · clinical trials

Kyverna Therapeutics clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA, UK, Germany, Brazil and Australia registers with Kyverna Therapeutics as lead sponsor. Synced 12 Nov 2026
3Current trials
2Recruiting now
3Drugs in these trials
5Trial registers
At a glance

Kyverna Therapeutics is the lead sponsor of 3 current clinical trials in our USA, UK, Germany, Brazil and Australia registers. 2 are recruiting patients now. The most common phase is Phase 2/3. The drugs named most often in its trials are KYV-101, Cyclophosphamide and Fludarabine. The most-studied condition is Myasthenia Gravis.

ClinicalTrials.gov trials by status

  • Recruiting267%
  • Active, closed133%

Trials by phase

  • Phase 2/3133%
  • Phase 2133%
  • Observational133%
01

Clinical trials sponsored by Kyverna Therapeutics

3 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
NCT06193889 · Myasthenia Gravis, Generalized Myasthenia Gravis
Phase 2/3 Recruiting 2024-08 UK, USA, Germany, Brazil, Australia
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
NCT07403188 · Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome
Drug: KYV-101
Observational Recruiting 2025-11 USA
KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
NCT06384976 · Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis
Drug: KYV-101
Phase 2 Active, closed 2024-09 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Kyverna Therapeutics trials

3 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Kyverna Therapeutics trials

10 conditions
Myasthenia Gravis1Generalized Myasthenia Gravis1Multiple Sclerosis, Primary Progressive1Multiple Sclerosis, Secondary Progressive1Multiple Sclerosis1MS1Refractory Lupus Nephritis1Myasthaenia Gravis1Stiff Person Syndrome1Rheumatoid Arthritis (RA)1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA32
Clinical trials in UK11
Clinical trials in Germany11
Clinical trials in Brazil11
Clinical trials in Australia11

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Myasthenia Gravis

SponsorTrials
argenx5
BioSensics1
Institut de Myologie, France1

Sponsors with the most current trials registered for this condition.

06

Questions about Kyverna Therapeutics trials

How many clinical trials does Kyverna Therapeutics sponsor?

Kyverna Therapeutics is the lead sponsor of 3 current trials on ClinicalTrials.gov in our USA, UK, Germany, Brazil and Australia registers, as of the registry sync on 12 November 2026. Completed and withdrawn studies are not counted.

Are Kyverna Therapeutics trials recruiting?

Yes. 2 of its 3 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Kyverna Therapeutics testing?

Its current trials name 3 drugs and biologicals as interventions. The most frequent are KYV-101 (3), Cyclophosphamide (1) and Fludarabine (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 12 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.